VOZMOZhNOSTI NEFROPROTEKTsII U PATsIENTOV S METABOLIChESKIM SINDROMOM
- 作者: Nedogoda SV1
-
隶属关系:
- 期: 编号 2 (2009)
- 页面: 26-30
- 栏目: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245804
- ID: 245804
如何引用文章
全文:
详细
Along with cardiovascular complications renal impairment is one of the most prognostic unfavorable metabolic syndrom's consequence. Approaches to chronic kidney disease progression in patients with metabolic syndrome are discussed
参考
- Mailloux L.U. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001;21:146-56.
- Kidney Disease Outcomes Quality Initiative (K/DOQI). Clinical practice guidelines on hypertension and antihy-pertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 Suppl. 1):S1-290.
- Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Invest Drugs 2000;9:2593-600.
- Joles J.A., Koomans H.A. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706.
- Ligtenberg G., Blankestijn P.J., Oey P.L., et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-28.
- Grisk O., Rettig R. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 2004;61:238-46.
- Wenzel R. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy Drugs 2005;65(Suppl. 2):29-39.
- Rubio-Guerra A.F., Trevino-Gomezharper C., Rodriguez-Lopez L., et al. Renoprotective effects of the combination trandolapril/verapamil in petints with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002;22(8):541-46.
- Rubio-Guerra A.F., Rodriguez-Lopez L., Arceo-Navarr A., et al. The effect of trandolapril and its fixed-dose combination with verapamil on the proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004;27(8):1688-91.
- The PROCOPA study group Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002;20:729-37.
- Schneider M., Lerch M., Papiri M., et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1995;14:669-77.
- Fernandez R., Puig J.G., Rodrigues-Perez J.C., et al. Effects of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001;15:849-56.
补充文件
